Coreline Soft published a study in the HANSE Lung Cancer Screening Trial using AVIEW quantitative CT biomarkers combined with clinical characteristics to improve COPD identification compared to emphysema alone.

Coreline Soft is a medical AI company specializing in chest CT analysis. We develop AI-powered solutions that support the earlier detection of lung cancer and the quantitative assessment of COPD and coronary artery calcification (CAC), helping clinicians make faster, more consistent, and better-informed decisions. Our flagship platform, AVIEW, is deployed at more than 500 clinical sites across 19 countries and has supported the analysis of over 3 million examinations. Coreline Soft’s solutions have received multiple U.S. FDA 510(k) clearances and CE marking under the EU Medical Device Regulation (MDR), enabling adoption across the United States, Europe, and other global markets. AVIEW is supported by a growing body of clinical evidence, including more than 500 peer-reviewed publications and scientific presentations. Founded in 2012, Coreline Soft combines clinical expertise and AI engineering to address real-world challenges in medical imaging and clinical workflows. Building on our expertise in chest CT, we are expanding the role of AI from detection and quantitative analysis to screening, longitudinal follow-up, and the management of diseases visible on chest CT.

Founded 2012